161.66 USD
-2.14 (-1.31%)
161.66 USD
0 (0%)
Overall RGEN gets a fundamental rating of 5 out of 10. We evaluated RGEN against 57 industry peers in the Life Sciences Tools & Services industry. RGEN has an excellent financial health rating, but there are some minor concerns on its profitability. RGEN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RGEN was profitable.
In the past year RGEN had a positive cash flow from operations.
RGEN had positive earnings in 4 of the past 5 years.
Each year in the past 5 years RGEN had a positive operating cash flow.
1.2 Ratios
RGEN's Return On Assets of 0.06% is fine compared to the rest of the industry. RGEN outperforms 68.42% of its industry peers.
RGEN has a Return On Equity of 0.08%. This is in the better half of the industry: RGEN outperforms 70.18% of its industry peers.
Looking at the Return On Invested Capital, with a value of 1.05%, RGEN is in line with its industry, outperforming 59.65% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for RGEN is significantly below the industry average of 13.99%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROIC | 1.05% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
With a decent Profit Margin value of 0.25%, RGEN is doing good in the industry, outperforming 68.42% of the companies in the same industry.
With a decent Operating Margin value of 6.58%, RGEN is doing good in the industry, outperforming 63.16% of the companies in the same industry.
In the last couple of years the Operating Margin of RGEN has declined.
RGEN's Gross Margin of 51.59% is in line compared to the rest of the industry. RGEN outperforms 59.65% of its industry peers.
RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RGEN is destroying value.
The number of shares outstanding for RGEN has been increased compared to 1 year ago.
Compared to 5 years ago, RGEN has more shares outstanding
The debt/assets ratio for RGEN has been reduced compared to a year ago.
2.2 Solvency
RGEN has an Altman-Z score of 7.40. This indicates that RGEN is financially healthy and has little risk of bankruptcy at the moment.
RGEN has a Altman-Z score of 7.40. This is amongst the best in the industry. RGEN outperforms 85.96% of its industry peers.
The Debt to FCF ratio of RGEN is 5.05, which is a neutral value as it means it would take RGEN, 5.05 years of fcf income to pay off all of its debts.
RGEN's Debt to FCF ratio of 5.05 is fine compared to the rest of the industry. RGEN outperforms 68.42% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
RGEN has a Debt to Equity ratio of 0.26. This is comparable to the rest of the industry: RGEN outperforms 50.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 7.4 |
ROIC/WACC0.1
WACC10.09%
2.3 Liquidity
RGEN has a Current Ratio of 8.36. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN has a better Current ratio (8.36) than 89.47% of its industry peers.
A Quick Ratio of 7.14 indicates that RGEN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.14, RGEN belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 21.17% over the past year.
RGEN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.11% yearly.
The Revenue has decreased by -8.54% in the past year.
Measured over the past years, RGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.62% on average per year.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
Based on estimates for the next years, RGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 25.53% on average per year.
RGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.90% yearly.
EPS Next Y14.9%
EPS Next 2Y19.58%
EPS Next 3Y22.57%
EPS Next 5Y25.53%
Revenue Next Year15.58%
Revenue Next 2Y14.07%
Revenue Next 3Y14.38%
Revenue Next 5Y15.9%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 97.39, the valuation of RGEN can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of RGEN is on the same level as its industry peers.
RGEN is valuated expensively when we compare the Price/Earnings ratio to 26.76, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 76.38, RGEN can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RGEN is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.96, RGEN is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 97.39 | ||
| Fwd PE | 76.38 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RGEN is on the same level as its industry peers.
RGEN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 85.46 | ||
| EV/EBITDA | 80.1 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as RGEN's earnings are expected to grow with 22.57% in the coming years.
PEG (NY)6.53
PEG (5Y)13.7
EPS Next 2Y19.58%
EPS Next 3Y22.57%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
161.66
-2.14 (-1.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners110.01%
Inst Owner Change16.45%
Ins Owners0.45%
Ins Owner Change-2.99%
Market Cap9.10B
Revenue(TTM)707.89M
Net Income(TTM)1.74M
Analysts81.43
Price Target191.72 (18.59%)
Short Float %7.79%
Short Ratio4.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.48%
Min EPS beat(2)-6.83%
Max EPS beat(2)7.78%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)4
Avg EPS beat(8)4.05%
EPS beat(12)8
Avg EPS beat(12)8.34%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)2
Avg Revenue beat(2)2.11%
Min Revenue beat(2)2.07%
Max Revenue beat(2)2.15%
Revenue beat(4)3
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)7
Avg Revenue beat(16)0.58%
PT rev (1m)5.52%
PT rev (3m)4.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10.44%
EPS NY rev (1m)-0.13%
EPS NY rev (3m)-1.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.09%
Revenue NY rev (1m)0.29%
Revenue NY rev (3m)0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 97.39 | ||
| Fwd PE | 76.38 | ||
| P/S | 12.85 | ||
| P/FCF | 85.46 | ||
| P/OCF | 69.52 | ||
| P/B | 4.37 | ||
| P/tB | 15.83 | ||
| EV/EBITDA | 80.1 |
EPS(TTM)1.66
EY1.03%
EPS(NY)2.12
Fwd EY1.31%
FCF(TTM)1.89
FCFY1.17%
OCF(TTM)2.33
OCFY1.44%
SpS12.58
BVpS37.01
TBVpS10.21
PEG (NY)6.53
PEG (5Y)13.7
Graham Number37.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROCE | 1.67% | ||
| ROIC | 1.05% | ||
| ROICexc | 1.43% | ||
| ROICexgc | 5.46% | ||
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% | ||
| FCFM | 15.04% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 37.9% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 117.95% | ||
| Profit Quality | 6126.58% | ||
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 | ||
| Altman-Z | 7.4 |
F-Score6
WACC10.09%
ROIC/WACC0.1
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
EPS Next Y14.9%
EPS Next 2Y19.58%
EPS Next 3Y22.57%
EPS Next 5Y25.53%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
Revenue Next Year15.58%
Revenue Next 2Y14.07%
Revenue Next 3Y14.38%
Revenue Next 5Y15.9%
EBIT growth 1Y163.23%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year69.07%
EBIT Next 3Y37.21%
EBIT Next 5Y36%
FCF growth 1Y9.1%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-10.84%
OCF growth 3Y13.8%
OCF growth 5Y21.15%
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status of REPLIGEN CORP (RGEN) stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the valuation of REPLIGEN CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for REPLIGEN CORP (RGEN) is 97.39 and the Price/Book (PB) ratio is 4.37.
Can you provide the expected EPS growth for RGEN stock?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 14.9% in the next year.